Is it possible to improve prognostic value of NCCN-IPI in patients with diffuse large B cell lymphoma? The prognostic significance of comorbidities-Reference-Cited by-同舟云学术

Is it possible to improve prognostic value of NCCN-IPI in patients with diffuse large B cell lymphoma? The prognostic significance of comorbidities

Published:2017-11-12 Issue:2 Volume:97 Page:267-276
ISSN:0939-5555
Container-title:Annals of Hematology
language:en
Short-container-title:Ann Hematol

Author:

Antic Darko^ORCID,Jelicic Jelena,Trajkovic Goran,Balint Milena Todorovic,Bila Jelena,Markovic Olivera,Petkovic Ivan,Nikolic Vesna,Andjelic Bosko,Djurasinovic Vladislava,Sretenovic Aleksandra,Smiljanic Mihailo,Vukovic Vojin,Mihaljevic Biljana

Funder

This work was supported by the Ministry of Science Project No 41004.

Publisher

Springer Science and Business Media LLC

Subject

Hematology,General Medicine

Link

http://link.springer.com/article/10.1007/s00277-017-3170-z/fulltext.html

Reference38 articles.

1. Shipp MA, Harrington DP, Anderson JR et al (1993) A predictive model for aggressive non-Hodgkin’s lymphoma. The International Non-Hodgkin’s Lymphoma Prognostic Factors Project. N Engl J Med 329:987–994

2. Sehn LH, Berry B, Chhanabhai M et al (2007) The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 109:1857–1861

3. Ziepert M, Hasenclever D, Kuhnt E et al (2010) Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era. J Clin Oncol 28:2373–2380

4. Zhou Z, Sehn LH, Rademaker AW et al (2014) An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood 123:837–842

5. Montalbán C, Díaz-López A, Dlouhy I et al (2017) Validation of the NCCN-IPI for diffuse large B-cell lymphoma (DLBCL): the addition of β2-microglobulin yields a more accurate GELTAMO-IPI. Br J Haematol 176:918–928

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Specific aspects of prognosis and treatment of elderly patients with large B-cell lymphoma;Medicinska istrazivanja;2024

2. Clinical Characteristics, Outcomes, and Risk Factors for Patients with Diffuse Large B-Cell Lymphoma and Development of Nomogram to Identify High-Risk Patients;Journal of Oncology;2022-11-17

3. Charlson Comorbidity Index (CCI) in Diffuse Large B-cell Lymphoma: A New Approach in a Multicenter Study;Indian Journal of Hematology and Blood Transfusion;2022-09-28

Statistical Challenges in Development of Prognostic Models in Diffuse Large B-Cell Lymphoma: Comparison Between Existing Models – A Systematic Review

;Clinical Epidemiology;2020-05

5. The Prognostic Impact of Comorbidities in Patients with De-Novo Diffuse Large B-Cell Lymphoma Treated with R-CHOP Immunochemotherapy in Curative Intent;Journal of Clinical Medicine;2020-04-02